Fluoxetine induces lipid metabolism abnormalities by acting on the liver in patients and mice with depression

Acta Pharmacologica Sinica

Volumn 39, Issue 9, 2018, Pages 1463-1472

  Pan, Shu juan ^b   Tan, Yun long ^b   Yao, Shang wu ^b   Xin, Yu ^a,c   Yang, Xuan ^a,c   Liu, Jing ^b   Xiong, Jing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

antidepressant; cholesterol; fluoxetine; low density lipoprotein; metabolic adverse reactions; triglyceride

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; FLUOXETINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; APOA1 PROTEIN, HUMAN; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; FEMALE; FORCED SWIM TEST; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HAMILTON DEPRESSION RATING SCALE; HAN CHINESE; HUMAN; INSULIN BLOOD LEVEL; LIPID LIVER LEVEL; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; LIVER TISSUE; MALE; MENTAL PATIENT; METABOLIC DISORDER; METABOLIC REGULATION; MOUSE; NONHUMAN; PROTEIN DETERMINATION; PSYCHOPHARMACOTHERAPY; SIDE EFFECT; SUCROSE PREFERENCE TEST; TAIL SUSPENSION TEST; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; ANALYSIS; ANIMAL; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG EFFECT; LIVER; METABOLISM;

ADULT; ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BLOOD GLUCOSE; CHOLESTEROL; DEPRESSION; FEMALE; FLUOXETINE; HUMANS; INSULIN; LIPID METABOLISM; LIPID METABOLISM DISORDERS; LIPOGENESIS; LIPOLYSIS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIVER; MALE; MICE, INBRED C57BL; SEROTONIN UPTAKE INHIBITORS; TRIGLYCERIDES;

EID: 85052302763     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2017.207     Document Type: Article

References (38)

1. Zunszain PA, Hepgul N, Pariante CM. Inflammation and depression. Curr Top Behav Neurosci 2013; 14: 135–51
2. DelMastro K, Hellem T, Kim N, Kondo D, Sung YH, Renshaw PF. Incidence of major depressive episode correlates with elevation of substate region of residence. J Affect Disord 2011; 129: 376–9
3. Sobocki P, Jonsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ 2006; 9: 87–98
4. Garrison GD, Levin GM. Factors affecting prescribing of the newer antidepressants. Ann Pharmacother 2000; 34: 10–4
5. Nassir F, Adewole OL, Brunt EM, Abumrad NA. CD36 deletion reduces VLDL secretion, modulates liver prostaglandins, and exacerbates hepatic steatosis in ob/ob mice. J Lipid Res 2013; 54: 2988–97
6. Richard J, Lingvay I. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther 2011; 9: 321–8
7. Estridge TB, Dey AB, Reidy C, Yu X, Zhang Y, Hartley M, et al. Identification of 4-aminopyrazolopyrimidine metabolite that may contribute to the hypolipidemic effects of LY2584702 in long evans diet-induced obese rats. J Pharmacol Exp Ther 2017; 362: 108–18
8. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125–31
9. Tang X, Li J, Xiang W, Cui Y, Xie B, Wang X, et al. Metformin increases hepatic leptin receptor and decreases steatosis in mice. J Endocrinol 2016; 230: 227–37
10. Quiroga AD, Lehner R. Role of endoplasmic reticulum neutral lipid hydrolases. Trends Endocrinol Metab 2011; 22: 218–25
11. Lehner R, Cui Z, Vance DE. Subcellullar localization, developmental expression and characterization of a liver triacylglycerol hydrolase. Biochem J 1999; 338: 761–8
12. Ko KW, Erickson B, Lehner R. Es-x/Ces1 prevents triacylglycerol accumulation in McArdle-RH7777 hepatocytes. Biochim Biophys Acta 2009; 1791: 1133–43
13. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013; 70: 31–41
14. Xiong J, Yang H, Wu L, Shang W, Shan E, Liu W, et al. Fluoxetine suppresses AMP-activated protein kinase signaling pathway to promote hepatic lipid accumulation in primary mouse hepatocytes. Int J Biochem Cell Biol 2014; 54: 236–44
15. Feng XM, Xiong J, Qin H, Liu W, Chen RN, Shang W, et al. Fluoxetine induces hepatic lipid accumulation via both promotion of the SREBP1c-related lipogenesis and reduction of lipolysis in primary mouse hepatocytes. CNS Neurosci Ther 2012; 18: 974–80
16. Xiao D, Chen YT, Yang D, Yan B. Age-related inducibility of carboxylesterases by the antiepileptic agent phenobarbital and implications in drug metabolism and lipid accumulation. Biochem Pharmacol 2012; 84: 232–9
17. Du RH, Tan J, Sun XY, Lu M, Ding JH, Hu G. Fluoxetine inhibits NLRP3 inflammasome activation: implication in depression. Int J Neuropsychopharmacol 2016; 19: pyw037
18. Li K, Shen S, Ji YT, Li XY, Zhang LS, Wang XD. Melatonin augments the effects of fluoxetine on depression-like behavior and hippocampal BDNF-TrkB signaling. Neurosci Bull 2017; 34: 303–11
19. Su WJ, Peng W, Gong H, Liu YZ, Zhang Y, Lian YJ, et al. Antidiabetic drug glyburide modulates depressive-like behavior comorbid with insulin resistance. J Neuroinflammation 2017; 14: 210
20. Masuda K, Nakanishi M, Okamoto K, Kawashima C, Oshita H, Inoue A, et al. Different functioning of prefrontal cortex predicts treatment response after a selective serotonin reuptake inhibitor treatment in patients with major depression. J Affect Disord 2017; 214: 44–52
21. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry 2002; 14: 175–82
22. Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999; 21: 643–58
23. Wong DT, Perry KW, Bymaster FP. Case history: the discovery of fluoxetine hydrochloride (Prozac). Nat Rev Drug Discov 2005; 4: 764–74
24. Farabaugh AH, Bitran S, Witte J, Alpert J, Chuzi S, Clain AJ, et al. Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. Int Clin Psychopharmacol 2010; 25: 214–7
25. Mallinckrodt CH, Goldstein DJ, Detke MJ, Lu Y, Watkin JG, Tran PV. Duloxetine: A new treatment for the emotional and physical symptoms of depression. Prim Care Companion J Clin Psychiatry 2003; 5: 19–28
26. Raeder MB, Bjelland I, Emil Vollset S, Steen VM. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J Clin Psychiatry 2006; 67: 1974–82
27. Fjukstad KK, Engum A, Lydersen S, Dieset I, Steen NE, Andreassen OA, et al. Metabolic abnormalities related to treatment with selective serotonin reuptake inhibitors in patients with schizophrenia or bipolar disorder. J Clin Psychopharmacol 2016; 36: 615–20
28. Le Melledo JM, Mailo K, Lara N, Abadia MC, Gil L, Van Ameringen M, et al. Paroxetine-induced increase in LDL cholesterol levels. J Psychopharmacol 2009; 23: 826–30
29. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005; 62: 190–8
30. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720–32
31. Pedrinola F, Sztejnsznajd C, Lima N, Halpern A, Medeiros-Neto G. The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial. Obes Res 1996; 4: 549–54
32. Visser M, Seidell JC, Koppeschaar HP, Smits P. No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obes Res 1994; 2: 152–9
33. O'Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 1994; 11: 105–10
34. Shahsavand Ananloo E, Ghaeli P, Kamkar MZ, Sadeghi M. Comparing the effects of fluoxetine and imipramine on total cholesterol, triglyceride, and weight in patients with major depression. Daru 2013; 21: 4
35. Olguner Eker O, Ozsoy S, Eker B, Dogan H. Metabolic effects of antidepressant treatment. Noro Psikiyatr Ars 2017; 54: 49–56
36. Kuehl LK, Muhtz C, Hinkelmann K, Dettenborn L, Wingenfeld K, Spitzer C, et al. Association between major depression and cardiovascular risk: the role of antidepressant medication. Psychopharmacology (Berl) 2016; 233: 3289–95
37. Kesim M, Tiryaki A, Kadioglu M, Muci E, Kalyoncu NI, Yaris E. The effects of sertraline on blood lipids, glucose, insulin and HBA1C levels: A prospective clinical trial on depressive patients. J Res Med Sci 2011; 16: 1525–31
38. Fell MJ, Anjum N, Dickinson K, Marshall KM, Peltola LM, Vickers S, et al. The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology (Berl) 2007; 194: 221–31